Dr. Anderson on Recent FDA Approvals in Multiple Myeloma

Dr. Anderson on Recent FDA Approvals in Multiple Myeloma

April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)Подробнее

April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

Multiple Myeloma: New Drugs on the HorizonПодробнее

Multiple Myeloma: New Drugs on the Horizon

Dr. Anderson on Recent Advances With Novel Therapies in Multiple MyelomaПодробнее

Dr. Anderson on Recent Advances With Novel Therapies in Multiple Myeloma

Dr. Lonial on the FDA Approval of Belantamab Mafodotin in Multiple MyelomaПодробнее

Dr. Lonial on the FDA Approval of Belantamab Mafodotin in Multiple Myeloma

Dr. Fonseca on FDA Approval of Daratumumab Triplets in Multiple MyelomaПодробнее

Dr. Fonseca on FDA Approval of Daratumumab Triplets in Multiple Myeloma

Dr. Kumar on Recent Advancements in the Field of Multiple MyelomaПодробнее

Dr. Kumar on Recent Advancements in the Field of Multiple Myeloma

MRD detection in myeloma: approval of NGS assay & questions for the clinicПодробнее

MRD detection in myeloma: approval of NGS assay & questions for the clinic

Highlight of CLL-related 2016 FDA approvals: VenetoclaxПодробнее

Highlight of CLL-related 2016 FDA approvals: Venetoclax